Jane Street’s Protagonist Therapeutics PTGX Stock Holding History

Jane Street’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.25M	Sell	10,200 -32,300	-76%	-$3.37M	﹤0.01%	6074
2026 Q1	$4.48M	Sell	42,500 -27,100	-39%	-$2.4M	﹤0.01%	3676
2025 Q4	$6.08M	Buy	69,600 +43,800	+170%	+$3.58M	﹤0.01%	2947
2025 Q3	$1.71M	Buy	25,800 +5,500	+27%	+$313K	﹤0.01%	5223
2025 Q2	$1.12M	Sell	20,300 -80,700	-80%	-$3.87M	﹤0.01%	5392
2025 Q1	$4.88M	Buy	+101,000	New	+$4.23M	﹤0.01%	2974
2023 Q3	–	Sell	-25,000	Closed	-$691K	–	9218
2023 Q2	$691K	Sell	25,000 -112,400	-82%	-$2.81M	﹤0.01%	5808
2023 Q1	$3.16M	Buy	+137,400	New	+$2.31M	﹤0.01%	3065
2022 Q3	–	Sell	-22,600	Closed	-$179K	–	10291
2022 Q2	$179K	Buy	+22,600	New	+$273K	﹤0.01%	8276
2022 Q1	–	Sell	-38,300	Closed	-$1.31M	–	10884
2021 Q4	$1.31M	Buy	+38,300	New	+$1.21M	﹤0.01%	5368

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Jane Street's PTGX Position: Q2 2026 in Review

Jane Street increased its Protagonist Therapeutics (PTGX) stake by 368% in Q2 2026, buying an estimated $1.39M and bringing the position to 16,882 shares worth $2.07M. The position accounts for ﹤0.01% of the portfolio, ranked #5106.

Jane Street first reported a position in PTGX in Q3 2016 and has held it in 22 quarters since. The position peaked at $9.35M in Q1 2025. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

Jane Street held 16,882 shares of Protagonist Therapeutics worth $2.07M as of Q2 2026.
Jane Street bought 13,275 Protagonist Therapeutics shares in Q2 2026, an estimated $1.39M.
Protagonist Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #5106 holding.
Jane Street first reported a position in Protagonist Therapeutics in Q3 2016 and has held it in 22 quarters since.
Jane Street's Protagonist Therapeutics position peaked at $9.35M in Q1 2025.
343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.